3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
3
Classical hematology
2
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Venous Thrombosis
1
Venous Thromboembolism
1
Vascular Diseases
1
Urogenital Neoplasms
1
Thromboembolism
1
Prostatic Neoplasms
1
Neoplasms
1
Myeloproliferative Disorders
1
Multiple Myeloma
1
Lymphoproliferative Disorders
1
Lymphoma
1
Lymphatic Diseases
1
Lung Neoplasms
1
Leukemia
1
Intestinal Neoplasms
1
Hemostatic Disorders
1
Digestive System Neoplasms
1
Colorectal Neoplasms
1
Breast Neoplasms
1
Interventions
Gemcitabine
2
Azacitidine
2
sargramostim
1
pemigatinib
1
pembrolizumab
1
motexafin gadolinium
1
incomplete Freund's adjuvant
1
cc-486
1
Trastuzumab
1
Tinzaparin
1
Quality of Life
1
Polymerase Chain Reaction
1
Patient Reported Outcome Measures
1
Panitumumab
1
Molecular Diagnostic Techniques
1
Injections
1
Immunotherapy
1
Immunoenzyme Techniques
1
Imatinib Mesylate
1
IFL protocol
1
Flow Cytometry
1
Epoetin Alfa
1
Drug Therapy
1
Doxorubicin
1
Docetaxel
1
Cisplatin
1
Cetuximab
1
Biological Therapy
1
Antineoplastic Protocols
1
4-phenylbutyric acid
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lung Neoplasms
×
Tinzaparin
×
Myeloid
×
Clear all
NCT03099031
2019-12-16
PREDICARE
LEO Pharma
Completed
420 enrolled